further source of bias. Each of the ocular risk factors seems to have a different degree of under-reporting and reporting bias. This will affect the estimates of relative and actual risk of PCR/VL for each of these ocular conditions. 
Response to the letter by Mr Depak Gupta, I would like to thank Mr Gupta, Dr Hadinapola and Mr Eke for their interest in our paper and the contribution of their unit in providing data for the study. 1 They have highlighted in a small survey of some of the doctors in their own department that not all carefully record all risk factors. They have not measured the accuracy of the responses, and therefore no firm conclusions can be drawn as to the magnitude of bias caused. Many of the risk factors identified in our study (1) are independent of the diligence of data recording by the surgeon (patient age, male gender, axial length 426 mm, use of alpha blockers) as they are recorded by nurses during pre-assessment and biometry or are highly likely to be recorded accurately (grade of surgeon). This leaves the following factors potentially susceptible to bias in their, and probably other units: (presence of glaucoma, diabetic retinopathy, brunescent/ white cataract, no fundal view/vitreous opacities, pseudoexfoliation and pupil size).
Accuracy of data is an issue in any study. As all data were anonymised before extraction it was not possible for us to evaluate the accuracy of the data. The Medisoft electronic patient record (EPR) system attempts to balance speed of data entry with completeness of data capture by using default settings for some fields, but by forcing data entry in important fields such as co-pathology and complications. Using EPR completeness of data capture can be guaranteed, but not accuracy. I am constantly looking for ways to design out potential sources of inaccurate data entry; for example, we may implement automatic selection of co-pathology options based on previously entered diagnoses, so that over time the accuracy of data entry in the EPR may improve. As EPR systems begin to entirely replace paper records, rather than just being used to audit specific care pathways, there will be increasing opportunities for cross-checking the accuracy of data entry.
Despite the potential for bias introduced by inaccurate data entry for some of the risk factors, it is gratifying that the authors recognise that the findings are 'broadly in line with our clinical experience'.
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The author is the Medical Director of Medisoft Limited. Sir, Case of novel PITX2 gene mutation associated with Peters' anomaly and persistent hyperplastic primary vitreous
The association of Peters' anomaly with persistent hyperplastic primary vitreous (PHPV) has been reported clinically and histopathologically, 1 but a genetic cause for the clinically uncommon complexation of these two malformations has not been reported.
A male child (3090 g) was born by normal gestation and delivery, and had no systemic abnormalities. His parents noted leukocoria in the right eye at the age of 7 days. Slit-lamp examination and ultrasound biomicroscopy showed central corneal opacity with anterior iris synechia, a shallow anterior chamber, lens subluxation, and elongated ciliary processes in the right eye (Figure 1a-c) . Computed tomography showed right microphthalmos.
Pars plana lensectomy and anterior vitrectomy were performed in the right eye at the age of 7 months to manage the pupillary block. Endoscopic findings revealed a persistent hyaloid artery towards the fibrovascular tissue behind the lens (Figure 1d ). On the basis of these findings, we diagnosed the child with Peters' anomaly-complicated PHPV.
After obtaining informed consent, molecular genetic analysis of the PITX2 gene by direct sequencing of all the coding regions revealed a novel 649C4A mutation in the proband (Figure 2 ). This substitution was not detected either in parents or in 72 healthy controls.
We postulate that the novel PITX2 gene mutation leads to migratory disorders of neural crest cells, which may result in both Peters' anomaly and PHPV, given the common mechanism underlying migratory disorders of neural crest cells and that which occurs during the critical period described for the diseases. 2 This hypothesis is consistent with recent findings that PITX2 expression in neural crest cells is observed not only in the anterior segment but also in the vitreous cavity at embryonic day 12.5 in mice. 3 Moreover, the deletion of 6p25, on which FOXC1 is located, which has a functional link with PITX2, 4 was reported to be associated with PHPV and Axenfeld-Rieger syndrome, 5 a syndrome thought to present the same spectrum of defects as Peters' anomaly.
We should carefully inspect the posterior segment in addition to the anterior segment in patients with congenital central corneal opacity. Molecular genetic analysis of PITX2 can help provide an accurate diagnosis of the diseases. 
